Primary Immune Deficiency (PID) – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 9 PAGES: 46

More Info
									Primary Immune Deficiency (PID) – Pipeline Review, H1 2012




    Primary Immune Deficiency (PID) – Pipeline Review,
                        H1 2012
                                                                                          Reference Code: GMDHC1697IDB
                                                                                            Publication Date: January 2012




Primary Immune Deficiency (PID) – Pipeline Review, H1 2012                                 GMDHC1697IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                            Page(1)
Primary Immune Deficiency (PID) – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 4
    List of Figures ................................................................................................................................................................................ 4
Introduction......................................................................................................................................................................................... 5
    Global Markets Direct Report Coverage ........................................................................................................................................ 5
Primary Immune Deficiency (PID) Overview ...................................................................................................................................... 6
Therapeutics Development................................................................................................................................................................. 7
    An Overview of Pipeline Products for Primary Immune Deficiency (PID) ...................................................................................... 7
Primary Immune Deficiency (PID) Therapeutics under Development by Companies......................................................................... 9
Primary Immune Deficiency (PID) Therapeutics under Investigation by Universities/Institutes ........................................................ 10
Late Stage Products ......................................................................................................................................................................... 11
    Comparative Analysis .................................................................................................................................................................. 11
Mid Clinical Stage Products.............................................................................................................................................................. 12
    Comparative Analysis .................................................................................................................................................................. 12
Early Clinical Stage Products ........................................................................................................................................................... 13
    Comparative Analysis .................................................................................................................................................................. 13
Primary Immune Deficiency (PID) Therapeutics – Products under Development by Companies..................................................... 14
Primary Immune Deficiency (PID) Therapeutics – Products under Investigation by Universities/Institutes ...................................... 15
Companies Involved in Primary Immune Deficiency (PID) Therapeutics Development ................................................................... 16
    Baxter International Inc................................................................................................................................................................ 16
    Octapharma AG........................................................................................................................................................................... 17
    CSL Limited ................................................................................................................................................................................. 18
    Biotest Pharmaceuticals Corporation .......................................................................................................................................... 19
Primary Immune Deficiency (PID) – Therapeutics Assessment ....................................................................................................... 20
    Assessment by Monotherapy Products ....................................................................................................................................... 20
    Assessment by Combination Products ........................................................................................................................................ 21
    Assessment by Route of Administration ...................................................................................................................................... 22
    Assessment by Molecule Type .................................................................................................................................................... 24
Drug Profiles..................................................................................................................................................................................... 27
    Gammagard Liquid + rHuPH20 - Drug Profile ............................................................................................................................. 27
         Product Description................................................................................................................................................................. 27
         Mechanism of Action ............................................................................................................................................................... 27
         R&D Progress ......................................................................................................................................................................... 27
    Cyclophosphamide + Allogeneic stem cell transplantation - Drug Profile .................................................................................... 29
         Product Description................................................................................................................................................................. 29
         Mechanism of Action ............................................................................................................................................................... 29
         R&D Progress ......................................................................................................................................................................... 29
    CYT107 - Drug Profile ................................................................................................................................................................. 30
         Product Description................................................................................................................................................................. 30
         Mechanism of Action ............................................................................................................................................................... 30
         R&D Progress ......................................................................................................................................................................... 30
    Mozobil - Drug Profile .................................................................................................................................................................. 31



Primary Immune Deficiency (PID) – Pipeline Review, H1 2012                                                                                    GMDHC1697IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Primary Immune Deficiency (PID) – Pipeline Review, H1 2012




         Product Description................................................................................................................................................................. 31
         Mechanism of Action ............................................................................................................................................................... 31
         R&D Progress ......................................................................................................................................................................... 31
    NewGam - Drug Profile ............................................................................................................................................................... 32
         Product Description................................................................................................................................................................. 32
         Mechanism of Action ............................................................................................................................................................... 32
         R&D Progress ......................................................................................................................................................................... 32
    Filgrastim + Plerixafor + Alemtuzumab + Hematopoietic Stem Cell Transplantation - Drug Profile ..........................
								
To top